When will Longeveron report earnings and how does it affect LGVN stock?

Longeveron will report 2025 results on March 17, 2026 after U.S. markets close. The earnings call and guidance will directly affect LGVN stock because the company is clinical-stage and price moves depend on cash runway and trial updates.

What is Meyka AI's forecast for LGVN stock and the implied change?

Meyka AI's forecast model projects **$0.36** for LGVN stock, versus the current price (USD **0.9735**), implying an approximate **-63.00%** downside. Forecasts are model-based projections and not guarantees.

What are the main risks investors should watch for in LGVN stock?

Primary risks are clinical trial outcomes, potential dilution from additional financings, and limited market-cap liquidity. LGVN stock is sensitive to single trial readouts and funding updates given the company’s clinical-stage profile.

How did the recent private placement affect LGVN stock outlook?

The private placement provided an initial **$15.00 million** tranche and extended runway into Q4 2026, reducing near-term financing pressure. The deal also links additional funding to HLHS milestones, which ties stock upside to trial progress.

US Stocks

LGVN Longeveron Inc. (NASDAQ) +20% to $0.97 Mar 13, 2026: earnings, runway

ByHuzaifa Zahoor March 14, 2026March 14, 2026

LGVN stock jumped on March 13, 2026 after Longeveron Inc. reported Q4 activity and closed a private placement that extended funding into late 2026. The share price moved to $0.97 on volume of 13,377,831 shares, up 20.33% for the day. Investors now focus on the company’s March 17, 2026 after-market earnings and how cash runway and the HLHS program will shape near-term valuation. We review financials, trading signals, and the company’s capital plan for the NASDAQ-listed biotechnology firm.